KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $24.0 million.

  • Rigel Pharmaceuticals' Net Cash Flow fell 131.16% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year decrease of 149.39%. This contributed to the annual value of $24.0 million for FY2024, which is 187.74% up from last year.
  • Rigel Pharmaceuticals' Net Cash Flow amounted to $24.0 million in FY2024, which was up 187.74% from $8.3 million recorded in FY2023.
  • Over the past 5 years, Rigel Pharmaceuticals' Net Cash Flow peaked at $24.0 million during FY2024, and registered a low of -$11.5 million during FY2021.
  • Its 3-year average for Net Cash Flow is $12.6 million, with a median of $8.3 million in 2023.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 246.24% in 2021, then skyrocketed by 187.74% in 2024.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Net Cash Flow stood at $7.9 million in 2020, then slumped by 246.24% to -$11.5 million in 2021, then soared by 148.50% to $5.6 million in 2022, then skyrocketed by 49.52% to $8.3 million in 2023, then spiked by 187.74% to $24.0 million in 2024.